Navigation Links
Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Date:10/22/2008

nts

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
4. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
5. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
6. ThreeWire Expands Presence in the Pharmaceutical Arena
7. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
8. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 Earlier ... for the promotion of hair regrowth in adult men ... classifications I-II or Norwood Hamilton classifications of IIa-V and ... an industry plagued by products that over-promise and under-deliver, ... Capillus272Pro™, renewing faith and confidence among more than 80 ...
(Date:3/27/2015)...   SurePure, Inc . (OTCQB: SURP), a ... the Company has completed the verification process and ... ("SURP") securities on OTCQB, an electronic quote and ... stage companies. On March 26, 2014, ... designed to improve marketplace integrity and enhance transparency ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Inc. (NYSE Amex: YMI ; TSX: YM) ... of 25,000,000 common shares of the Company, for total ... with the offering, the Company also granted the underwriters ... common shares to cover over-allotments, if any. The Company ...
... Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx Co.), ... of sleep related breathing disorders (SRBDs), announced today the ... & President and his election to the Board of ... will be responsible for spearheading the clinical, regulatory, IP ...
... Catal de Nanotecnologia (ICN), in Barcelona, has demonstrated a device ... key step in developing the spin computers of the future. ... the journal Science. The authors are Marius V. Costache and ... the Physics and Engineering of Nanodevices Group at ICN. ...
Cached Biology Technology:YM BioSciences Closes Public Offering of Common Shares 2YM BioSciences Closes Public Offering of Common Shares 3Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director 2A 'spin ratchet': A new electronic structure for generating spin current 2
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/12/2015)... March 12, 2015 Beta ... identity and access management (IAM) solution for a ... With Beta System,s new IAM package, customers benefit ... gleaned from multiple IAM implementations across different industries. ... as well as any necessary services and consulting. ...
(Date:3/11/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ... Control Market by Product, Application & By Geography - ... their offering. , This report predicts that ... billion by 2020, with an estimated CAGR of 10.6%. ... products types such as contact cards & readers, contactless ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... BOULDER--Large-scale fires in a western or southeastern state can ... a few weeks as the state,s entire motor vehicle ... research by scientists at the National Center for Atmospheric ... The paper, "Estimates of CO2 from fires in ...
... they could detect toxic levels of acetaminophen in laboratory ... This study by the National Institute of Environmental Health ... could be a first step in developing accurate new ... of acetaminophen, the active ingredient in many over-the-counter pain ...
... YORK -- Researchers have discovered the secrets to ... programs. A three-year study entitled "Greener Voices" proves ... when given responsibility for decision making and planning. ... past two decades. Gardens are popping up in ...
Cached Biology News:US fires release large amounts of carbon dioxide 2US fires release large amounts of carbon dioxide 3Unique pattern of gene expression can indicate acetaminophen overdose 2Children's gardens mushrooming 2
... large numbers of samples may be carried out ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... Highly nutritious peptone, used ... production of bacterial toxins, ... of bacteria with high ... Haemophilus, Neisseria, Pasteurella, Salmonella ...
... Human Raji cells were cultured in RPMI 1640 ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... Human 293 cells were cultured in Minimum ... harvested at the log phase of growth. ... native forms, cells were fixed in acetone-methanol. ... mm) adhesive coated slide, with each wells surface ...
Biology Products: